NiteWatch home sleep testing service receives Joint Commission accreditation as an 'Ambulatory Health Care Programme'

Neuhausen am Rheinfall 23 November 2009LifeWatch AG, a provider of wireless cardiac and other medical monitoring services in the United States, has had accredit its "NiteWatch" home sleep testing service with the Joint Commission for "Ambulatory Health Care Programmes", and is one of only a few independent diagnostic testing facilities (IDTFs) which have received this Gold Seal of Approval.


"Joint Commission certification endorses LifeWatch as an organisation committed to clinical excellence and quality", stated Marikay Menard, Vice President of Clinical Strategy and Regulatory Affairs of LifeWatch Services Inc. "The expansion of this certification to our NiteWatch Home Sleep Testing service confirms this commitment to quality as we expand our medical service offering to home sleep testing in the first quarter of 2010."

The Joint Commission on Accreditation of Healthcare Organizations evaluates and accredits nearly 17.000 health care organisations and programmes in the United States. As an independent, not-for-profit organisation, the Joint Commission is the nation's predominant standards-setting and accrediting body in health care.

"This additional accreditation further demonstrates LifeWatch's commitment to provide patients with the highest quality clinical services in the industry", stated Dr. Yacov Geva, Chairman and Chief Executive Officer of LifeWatch AG.

NiteWatch provides home sleep testing for diagnosing Obstructive Sleep Apnea (OSA), a widely undiagnosed medical condition that is highly correlated with other chronic diseases. Thirty eight million Americans are affected by OSA, of which fifteen million are undiagnosed. The United States market for OSA is currently estimated at USD 1,5 billion, out of which an estimated one million tests are conducted annually. This market is projected to grow between 20-50 percent in the next five years, with home sleep testing capturing approximately 20 percent of the total market.

LifeWatch, as the first Cardiac IDTF to enter into home sleep testing services, will leverage its medical monitoring expertise into a competitive advantage, and diversify LifeWatch's service offering. LifeWatch is fully on track with its planned roll out of the NiteWatch service and has expanded its beta launch to 12 clients and is now approaching 50 patients. The company has already signed 166 commercial managed care contracts covering 90 million lives for its new NiteWatch service and will continue to broaden coverage with additional contracts.

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on SIX Swiss Exchange (LIFE), Switzerland, is a health care technology and solution company, specializing in advanced telehealth systems and wireless remote patient monitoring services. LifeWatch services treat high-risk and chronically ill patients, health conscious consumers and wellness programmes. LifeWatch has subsidiaries in the United States, The Netherlands, Japan, the United Kingdom, Switzerland and Israel.

LifeWatch AG is the parent company of LifeWatch Services Inc., a United States-based cardiac monitoring service provider, and manufacturer of telecardiology products. LifeWatch is also introducing a new programme for home sleep testing of Obstructive Sleep Apnea (OSA) patients under the brand name NiteWatch. More company news is available in the VMW July 2009 article LifeWatch and Verizon Wireless to expand health care telemedicine solutions.

Source: LifeWatch

[Medical IT News][Calendar][Virtual Medical Worlds Community][News on Advanced IT]